Red light therapy for fibromyalgia works by targeting the cellular dysfunction behind the condition's most debilitating symptoms. If you live with fibromyalgia, you already know the pattern: pain that medications manage but rarely resolve, fatigue that persists despite rest, and the emotional toll that accumulates when both continue long enough. The therapy addresses these symptoms at their biological source. Red and near-infrared wavelengths penetrate tissue and stimulate energy production inside cells, reduce inflammation signaling, lower cellular stress, and modulate the way the nervous system processes pain. These are the same biological processes that fibromyalgia research has identified as disrupted in patients with the condition.
This article is part of our complete guide to Red and Infrared Light Therapy for Fibromyalgia.
Key Takeaways
- Clinical evidence: A meta-analysis of 9 randomized controlled trials (Yeh et al., 2019) found large, statistically significant improvements across pain (SMD 1.18), function (SMD 1.16), fatigue (SMD 1.40), depression (SMD 1.46), and anxiety (SMD 1.46). A 2025 umbrella review of 204 RCTs (Son et al.) rated the evidence for photobiomodulation's effect on fibromyalgia fatigue at moderate certainty, the highest tier achieved in the analysis, and described fibromyalgia as among the conditions with the strongest evidentiary support.
- Primary mechanism: Red light (630–660nm) stimulates a key enzyme in the cell's energy-production chain, boosting cellular energy output. This leads to reduced inflammation signaling, lower cellular stress, and enhanced tissue repair, addressing the multi-system cellular dysfunction documented in fibromyalgia patients across muscle tissue (Gerdle et al., 2020), skin biopsies (Sánchez-Domínguez et al., 2015), and blood cells (Cordero et al., 2010).
- Current boundaries: No study has yet measured photobiomodulation's effect on inflammatory markers in fibromyalgia patients specifically; the anti-inflammatory evidence comes from other populations and the overlap is inferred. No study has tested photobiomodulation on small fiber pathology outcomes in fibromyalgia. The individual trials underpinning the meta-analyses generally had small sample sizes and methodological limitations that the Yeh meta-analysis itself acknowledged.
Understanding Fibromyalgia: Why Conventional Treatments Leave Gaps
Fibromyalgia produces widespread pain, persistent fatigue, sleep disruption, and cognitive difficulties that fluctuate unpredictably. The condition is real, measurable, and now supported by objective findings across multiple tissue types.
The biology is genuinely multi-system. Research has documented central sensitization, where the nervous system amplifies pain signals beyond what the stimulus warrants. Peripheral inflammation is present, with elevated levels of key inflammation signals confirmed in meta-analysis. Mitochondrial dysfunction (reduced cellular energy production) has been measured in muscle, skin, and blood cells. And defective endogenous pain modulation means the body's built-in pain-dampening systems are not functioning normally.
Conventional treatment typically combines FDA-approved medications (pregabalin, duloxetine, or milnacipran), exercise, and cognitive behavioral therapy. These help many patients manage symptoms, but none addresses the underlying cellular dysfunction that fibromyalgia research has increasingly identified. Most approved treatments target one system. The condition disrupts several simultaneously. That mismatch between single-target treatments and multi-system pathology is what makes the photobiomodulation research worth examining closely.
What caught my attention is the range of the clinical response. Pain, fatigue, depression, anxiety, function: all showing large effect sizes in the same patients. That's unusual. The approved medications tend to move one or two of those. When you look at what's actually disrupted in fibromyalgia and what this therapy targets at the cellular level, the multi-domain improvement starts to make biological sense.— Dr. William Carter, MD
Boosting Cellular Energy in Fatigued Tissue
Fatigue is the symptom most consistently reported by fibromyalgia patients alongside pain. The 2025 umbrella review (Son et al.) rated the evidence for photobiomodulation's effect on fibromyalgia fatigue at moderate certainty, the highest tier achieved in the analysis, with the largest effect size (eSMD 1.25) among musculoskeletal outcomes. The review's conclusion described fibromyalgia as among the conditions with the strongest evidentiary support. An umbrella review synthesizes systematic reviews and meta-analyses, the widest-angle lens the evidence hierarchy offers, and at that altitude, fibromyalgia fatigue stood out.
The mechanism traces to the mitochondria, the energy-producing structures inside every cell. Red light at 630–660nm is absorbed by a key enzyme in the cell's energy-production chain, increasing energy output while releasing signaling molecules that reduce inflammation. In stressed or diseased tissue, where one of these molecules accumulates and blocks the enzyme from functioning normally, photobiomodulation clears the blockage and restores energy production. The therapy's effects are more pronounced in compromised cells than in healthy ones, a principle established by Karu (2013) and explained mechanistically by de Freitas and Hamblin (2016). Hamblin (2017), in a widely cited review in AIMS Biophysics, confirmed that photobiomodulation produces measurable increases in cellular energy output and detailed the anti-inflammatory effects that follow from restored cell function.
For fibromyalgia specifically, this energy deficit spans tissue types. Gerdle et al. (2020) used tissue sampling and specialized muscle imaging in 33 fibromyalgia patients versus 31 controls and found significantly lower concentrations of key energy molecules in back muscle, alongside reduced blood flow and elevated markers of impaired energy metabolism. Cordero et al. (2010) measured a critical energy-production molecule at 40–50% of normal levels in blood cells from fibromyalgia patients, with mitochondrial dysfunction and increased cellular stress accompanying the deficit. Skin biopsies told the same story: Sánchez-Domínguez et al. (2015) confirmed cellular stress and mitochondrial dysfunction in a separate tissue compartment entirely. And a 2025 review by Ho et al. in Frontiers in Pain Research concluded that growing evidence implicates cellular stress and mitochondrial dysfunction as key contributors to fibromyalgia's underlying biology. Calling this a "cascade" from mitochondria to symptoms makes it sound more linear than it is; whether the dysfunction is a primary driver or downstream of deconditioning and central sensitization is unresolved, but the measured energy deficits across muscle, skin, and blood are established regardless of where they sit in the causal chain.
The largest fibromyalgia RCT (Silva et al., 2018) enrolled 160 women and delivered multi-wavelength photobiomodulation including 640nm red LEDs to 11 tender point locations across the body. Both photobiomodulation and exercise improved pain thresholds across multiple tender points. The combined therapy group showed the most substantial effects, with improvements in both pain and function scores as well as quality of life over 10 weeks. That combination result matters. Exercise demands cellular energy. Photobiomodulation helps cells produce it. The mechanism predicts they should work together, and the trial data confirms it.
Reducing Inflammatory Signaling
Fibromyalgia is not traditionally classified as an inflammatory condition, but the evidence for a persistent inflammatory component is now substantial. O'Mahony et al. (2021), in a systematic review and meta-analysis published in Rheumatology, found that fibromyalgia patients have significantly elevated levels of two key inflammation signals compared to healthy controls, with both findings holding up under rigorous re-testing. A third inflammation signal also showed elevation, but the authors noted that result was less statistically stable, a distinction that matters when characterizing the inflammatory profile. A separate meta-analysis by Andrés-Rodríguez et al. (2019) in Brain, Behavior, and Immunity confirmed these findings across multiple immune markers. The inflammation is real.
Photobiomodulation reduces these inflammation signals in other clinical populations. Cheng et al. (2021), in a narrative review published in The Journal of Pain, traced the pathways through which photobiomodulation suppresses key inflammation signals through modulation of the body's inflammatory response. Pigatto et al. (2019) demonstrated in an animal model that photobiomodulation therapy reduces acute pain and inflammation through measurable suppression of these same signals.
The inflammatory markers elevated in fibromyalgia overlap with the markers that photobiomodulation suppresses in other contexts. The clinical outcome data (reduced pain, improved function) is confirmed across multiple trials. What remains untested is the direct measurement of inflammatory marker changes in fibromyalgia patients receiving photobiomodulation, and until that study is conducted, the mechanistic link between these two literatures stays inferential.
Modulating Pain Signaling
The pain in fibromyalgia extends beyond inflammation. Central sensitization amplifies pain signals so that stimuli that should not be painful become painful, and stimuli that should be mildly painful become severe. O'Brien et al. (2018) confirmed in a meta-analysis that fibromyalgia patients have impaired built-in pain control.
Red light therapy engages the body's built-in pain control system. Oono et al. (2023), in Lasers in Medical Science, found that photobiomodulation significantly strengthened this pain-dampening response in healthy volunteers (p < 0.05). The effect was specific to the pain-dampening pathway. Two other pain-processing measures did not reach significance, and the sample was small (n=30), placing this as a preliminary signal that the mechanism is engaged. Buzza et al. (2024), in Neuromodulation, found that direct photobiomodulation on the sciatic nerve significantly reduced acute pain sensitivity (70% reduction) with no statistically significant effect on motor function, demonstrating that the therapy selectively targets pain signaling at the nerve level, though the motor experiment used only 4 animals per group, limiting the power to rule out small motor effects.
The clinical translation of these pain-modulating effects is visible in the trial data. The 2019 Yeh meta-analysis found large effect sizes for pain reduction (SMD 1.18). The triple-blinded Navarro-Ledesma trial (2022) found pain reduction at p ≤ 0.001 after whole-body photobiomodulation. And the six-month follow-up trial (n=42) found that quality of life and self-efficacy persisted throughout follow-up, with pain reaching significance at six months (p = 0.001, Cohen's d = 1.16) after a non-significant result at three months (p = 0.17), a trajectory the authors noted but did not explain, and which makes the six-month durability finding more interesting rather than less, because whatever drove the delayed pain response operated on a different timescale than the functional and psychological improvements that appeared earlier.
Addressing Small Fiber Pathology
An estimated 49% of fibromyalgia patients show evidence of small fiber pathology, abnormalities in the smallest nerve fibers, as found in a pooled analysis of 8 studies with 222 participants by Grayston et al. (2019), with a 95% confidence interval of 38–60%.
This is relevant because photobiomodulation has demonstrated nerve-protective and nerve-repair effects. Chacur et al. (2024), in Physiology & Behavior, demonstrated that near-infrared photobiomodulation (850nm) both prevented and reversed nerve pain behavior in a validated animal model (nerve compression injury), with high-resolution imaging conducted to evaluate potential structural changes in sciatic nerve tissue. The study used a nerve damage model rather than fibromyalgia specifically, but the finding is directly relevant to the subset of fibromyalgia patients with documented small fiber pathology. No study has yet tested photobiomodulation's effect on small fiber pathology outcomes in fibromyalgia patients directly. (For the evidence on near-infrared light's deeper-tissue effects, see Infrared Light Benefits for Fibromyalgia.)
How These Mechanisms Connect to Clinical Outcomes
Each mechanism addresses a distinct component of the fibromyalgia symptom profile. ATP production targets the cellular energy deficit documented across muscle, skin, and blood cells. Anti-inflammatory effects target the TNF-α and IL-8 elevations confirmed in meta-analysis. Pain modulation addresses the central sensitization and defective endogenous pain control. Nerve-level effects are relevant to the small fiber pathology present in a substantial subset of patients.
This is why the 2019 meta-analysis found large effect sizes across five different symptom domains: the mechanisms are broad enough to reach each one. (For the full clinical evidence base, see PBM for Fibromyalgia: Clinical Evidence. For safety data, see Photobiomodulation Safety for Fibromyalgia.)
Where the Evidence Stands
The biological case for red light therapy in fibromyalgia rests on a genuine alignment between what the therapy does at the cellular level and what the research has found to be disrupted in patients with the condition. The clinical evidence (large effect sizes across pain, function, fatigue, depression, and anxiety in meta-analysis; moderate-certainty evidence for fatigue in a 2025 umbrella review; durable improvements at six-month follow-up) is stronger than what exists for most non-pharmaceutical interventions in fibromyalgia. The mechanistic evidence explaining why the therapy works is well-documented in adjacent contexts, with specific confirmation in fibromyalgia patients still developing. That combination of strong clinical data and plausible biological mechanism is the framework you need to evaluate this therapy alongside whatever else you are considering or already doing for your symptoms.
